From
Plumb's Veterinary Drug Handbook (
2008 edition), pp. 415-417. Do take note that this information is 12 years old.
I copied and pasted from a PDF. I cleaned it up a bit but there are still a few line separating hyphens and capitalizations I have not done. Sorry, recently out of hospital (not virus related) and not quite back on my feet yet. The information may not look right in places but should be readable.
p. 415
gabapentin
(gab-ah-pen-tin) Neurontin® ANTIcONvuLSANT; NeuROPAThIc
PAIN ANALGeSIc
prescriber Highlights
May be useful in dogs & cats as adjunctive therapy for refractory or complex partial seizures or the treatment of pain
Caution in patients with diminished renal function, but dogs partially (30–40%) metabolize the drug (humans do not)
Avoid use of xylitol-containing oral liquid in dogs
Sedation most likely adverse effect, but adverse effect
profile not well-defined for animals
Expense may be a significant issue, but may decrease as generics are now available
uses/indications
Gabapentin may be useful as adjunctive therapy for refractory or complex partial seizures, or in the treatment of chronic pain in dogs or cats.
pharmacology/actions
Gabapentin has analgesic effects and can prevent allodynia (sensa- tion of pain resulting from a normally non-noxious stimulus) or hyperalgesia (exaggerated response to painful stimuli). It also has anticonvulsant activity. The mechanism of action of gabapentin, for either its anticonvulsant or analgesic actions is not understood. While gabapentin is structurally related to GABA, it does not ap- pear to alter GABA binding, reuptake, or degradation, or serve as a GABA agonist in vivo.
pharmacokinetics
In dogs, oral bioavailability is about 80% at a dose of 50 mg/kg. Peak plasma levels occur about 2 hours post dose. Elimination is primarily via renal routes, but gabapentin is partially metabolized to N-methyl-gabapentin. Elimination half-life is approximately 2 – 4 hours in dogs. No pharmacokinetic data for cats was located. In humans, gabapentin bioavailability decreases as dosage increas- es. At doses of 900 mg/day, 60% of the dose is absorbed. Percentage absorbed is reduced as doses are increased to a minimum of 27%
(p. 416 gabapentin)
of the dose being absorbed when 4800 mg/day is administered. Presence of food only marginally alters absorption rate and extent of absorption. Gabapentin is only minimally bound to plasma pro- teins; CSF levels are approximately 20% of those in plasma. The drug is not significantly metabolized and is almost exclusively ex- creted unchanged into the urine. Elimination half-lives in humans are approximately 5 – 7 hours.
contraindications/precautions/Warnings
Gabapentin is considered contraindicated in patients hypersensi- tive to it. Because gabapentin is eliminated via renal routes (practi- cally 100% in humans), it should be used with caution in patients with renal insufficiency; if required, dosage adjustment should be considered. In dogs, the drug is also metabolized (30 – 40%) of a dose, so dosage adjustment may not be required in dogs with mild to moderate renal dysfunction.
In general, avoid the use of the commercially available human oral solution (Neurontin®) in dogs as it reportedly contains 300 mg/ mL xylitol. As the threshold dose that can cause hypoglycemia in dogs is approximately 100 mg/kg, doses of up to 15 mg/kg in dogs using the solution should be safe, but further data is needed to con- firm this. Additionally, xylitol may be hepatotoxic in dogs. Doses of 500 mg/kg of xylitol are currently thought to be the threshold for this toxicity, but there have been anecdotal reports of it occurring at much lower doses. In cats, at the dosages used presently, xylitol toxicity does not appear to be a problem with gabapentin oral solu- tion, but use with caution.
adverse effects
Sedation is probably the most likely adverse effect seen in small ani- mals. Starting the dose at the lower end of the range and increasing with time, may alleviate this effect. In humans, the most common adverse effects associated with gabapentin therapy are dizziness, somnolence, and peripheral edema.
Gabapentin was associated with an increased rate of pancreatic adenocarcinoma in male rats. It is unknown if this effect crosses into other species.
Abrupt discontinuation of the drug has lead to withdrawal-pre- cipitated seizures. In humans, it is recommended to wean off the drug when it is used for epilepsy treatment.
Reproductive/nursing Safety
In humans, the FDA categorizes gabapentin as a category C drug for use during pregnancy (Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal reproduction studies and no adequate studies in humans). At high dosages (at or above human maximum dosages), gabapen- tin was associated with a variety of fetotoxic and teratogenic effects (e.g., delayed ossification, hydronephrosis, fetal loss) in rats, mice and rabbits.
Gabapentin enters maternal milk. It has been calculated that a nursing human infant could be exposed to a maximum dosage of 1 mg/kg/day. This is 5 – 10% of the usual pediatric (>3 yrs old) thera- peutic dose. In veterinary patients, this appears unlikely to be of significant clinical concern.
overdosage/acute toxicity
In humans, doses of up to 49 grams have been reported without fatality. Most likely effects include ataxia, lethargy/somnolence, di- arrhea, etc.
The commercially available oral solution contains 300 mg/mL; doses of 0.33 mL/kg may cause hypoglycemia or liver toxicity in dogs.
There were 256 exposures to gabapentin reported to the ASPCA Animal Poison Control Center (APCC;
www.apcc.aspca.org) during 2005 – 2006. In these cases 211 were dogs with 13 showing clinical signs and the remaining 45 cases were cats with 11 show- ing clinical signs. Common findings in dogs recorded in decreasing frequency included lethargy, ataxia, sedate, vomiting and bulging eyes. Common findings in cats recorded in decreasing frequency included ataxia, lethargy, bradycardia, depression, and mydriasis. Treatment is basically supportive with general decontamination procedures including emesis, activated charcoal, and cathartics. The drug can be removed with hemodialysis.
Drug interactions
The following drug interactions have either been reported or are theoretical in humans or animals receiving gabapentin and may be of significance in veterinary patients:
antaciDS: Oral antacids given concurrently with gabapentin may decrease oral bioavailability by 20%; if antacids are required, separate doses at least 2 hours from gabapentin
HyDRocoDone: Co-administration of gabapentin and hydrocodone may increase the AUC (area under the curve) of gabap- entin and increase the efficacy and/or adverse effects of the drug. Gabapentin can reduce the AUC of hydrocodone, potentially re- ducing the drug’s effectiveness.
moRpHine: May increase gabapentin levels
laboratory considerations
There are reports of gabapentin causing false-positive urinary protein readings on Ames N-Multistix SG dipstick tests. The use of a sulfosalicylic acid precipitation test to determine presence of urine protein is recommended for patients receiving gabapentin.
Doses
DogS:
For ancillary therapy of refractory seizures:
a) 10 – 30 mg/kg PO q8 – 12h (Podell 2006a)
b) 25–60 mg/kg/day PO divided q6–8h, the author initially uses 10 mg/kg PO q8h. (Dewey 2005b)
c) 10 – 30 mg/kg PO q8h. note: expensive and of limited benefit (Berry 2003)
As an analgesic:
a) For adjunctive treatment of chronic or cancer pain: 3 mg/kg PO once a day (Lascelles 2003)
b) 1.25 – 10 mg/kg PO q24h (once daily) (Hardie 2006)
catS:
For ancillary therapy of refractory seizures:
a) 5 mg/kg PO three times daily (Pearce 2006b)
b) 5 – 10 mg/kg PO q8 – 12h (Podell 2006a)
c) 10 – 30 mg/kg PO q8h (note: expensive and of limited benefit) (Berry 2003)
As an analgesic:
a) 1.25 – 10 mg/kg PO q24h (once daily) (Hardie 2006)
b) For adjunctive treatment of chronic or cancer pain: 3 mg/kg PO once a day (Lascelles 2003), (Hardie, Lascelles et al. 2003)
c) For adjunctive analgesia associated with neuropathic pain:
While suggested range in cats is 2.5 – 5 mg/kg PO q12h, this author starts at 5 mg/kg and increases (up to 10 mg/kg) if no effect seen in two hours. May be a higher requirement in cats for post-seizure or CPR vocalization and thrashing. Wean off slowly or patient may experience worse pain. Reduce in renal insufficiency. Usually the limit of dosing is reached when pa- tient is sedated. (Mathews 2006)
(p. 217)
monitoring
note: Gabapentin serum levels are not monitored at present.
Clinical efficacy and adverse effects should be monitored.
client information
Clients should report any significant adverse effects such as ataxia or hypersomnolence